Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

2.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

3.

Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes.

Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J, Skyler JS, Clare-Salzler M; Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group.

Pediatr Diabetes. 2015 Jun;16(4):271-9. doi: 10.1111/pedi.12170. Epub 2014 Jul 12.

4.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

5.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

6.

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; Type 1 Diabetes TrialNet Anti CD-20 Study Group.

J Clin Virol. 2013 Jun;57(2):115-9. doi: 10.1016/j.jcv.2013.01.016. Epub 2013 Feb 17.

7.

Effect of rituximab on human in vivo antibody immune responses.

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A; Type 1 Diabetes TrialNet Study Group.

J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008. Epub 2011 Sep 9.

8.

Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2009 Sep;32(9):1603-7. doi: 10.2337/dc08-2140. Epub 2009 Jun 1.

9.

Type 1 Diabetes TrialNet--an international collaborative clinical trials network.

Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L; Type 1 Diabetes TrialNet Study Group.

Ann N Y Acad Sci. 2008 Dec;1150:14-24. doi: 10.1196/annals.1447.054.

10.

Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes.

Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA; DPT-1 Study Group.

Pediatr Diabetes. 2009 May;10(3):177-83. doi: 10.1111/j.1399-5448.2008.00463.x. Epub 2008 Sep 24.

11.

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group.

Pediatr Diabetes. 2009 Apr;10(2):97-104. doi: 10.1111/j.1399-5448.2008.00464.x. Epub 2008 Sep 24.

PMID:
18823409
12.

Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler JS.

Diabetes Care. 2008 Nov;31(11):2188-92. doi: 10.2337/dc08-0935. Epub 2008 Jul 23.

13.

Participant and parent experiences in the parenteral insulin arm of the diabetes prevention trial for type 1 diabetes.

Johnson SB, Baughcum AE, Hood K, Rafkin-Mervis LE, Schatz DA; DPT-1 Study Group.

Diabetes Care. 2007 Sep;30(9):2193-8. Epub 2007 Jun 11.

PMID:
17563348
14.

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E.

Diabetes Care. 2005 May;28(5):1068-76.

PMID:
15855569
Items per page

Supplemental Content

Loading ...
Write to the Help Desk